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Abstract. Transarterial chemoembolization with irinotecan 
loaded beads (DEBIRI-TACE) represents an investigative 
treatment option for patients with metastatic colorectal cancer 
(mCRC). The present study examined DEBIRI-TACE with 
concomitant mFOLOFX6‑bevacizumab as a first‑line treat-
ment for mCRC and explored the clinical value of circulating 
cell-free DNA (cfDNA). Patients with limited mCRC of the 
liver who had not been treated with chemotherapy received 
up to 4 biweekly DEBIRI-TACE treatments. The endpoints 
examined included the response rate, survival, toxicity and 
translational analysis. Due to toxicity and lack of feasibility, 
the study closed prematurely. Total cfDNA was measured 
with a direct fluorescent assay. Between December 2012 
and February 2014, 14 patients underwent a total of 
49 DEBIRI-TACE treatments. With a median follow-up of 
1.7 years, the median progression free survival and overall 
survival (OS) were 240 days [95% confidence interval (CI): 
161-357] and 522 days (95% CI: 174-1,054), respectively. The 
response rate was 50%. Twelve patients experienced grade 3 
toxicity or above. Dynamics of cfDNA showed biological vari-
ations in relation to therapy. To conclude, the present results 
indicated a response rate of 50% and median OS of 522 days 
for 14 patients with mCRC undergoing DEBIRI-TACE, but 
unacceptable toxicity and lack of feasibility with the applied 
schedule. The findings suggest that the level of cfDNA may 
be associated with the disease course, response to treatment 
and outcome. Trial registration: The European Clinical Trials 
database (EudraCT no. 2012-000987-11) at 05-14-2012.
Introduction
Colorectal cancer (CRC) remains one of the most common 
malignant diseases with approximately 400,000 new cases 
word wide yearly (1). Close to 50% of patients diagnosed with 
CRC develop metastatic disease (mCRC) with the liver being 
the predominant organ affected (2). Surgical resection of liver 
metastases results in long term survival for about 40% (3) 
but only a minority of patients are eligible for resection. This 
has stimulated the interest in non-surgical local treatments 
including radiofrequency ablation (RFA) (4) and stereotactic 
body radiotherapy (SBRT) (5), both of which are established 
as standard of care.
Trans arterial chemo-embolization (TACE) was intro-
duced in the 1980's by Yamada (6) with the rationale of 
embolic induced ischemia and necrosis and the delivery of 
chemotherapy with a minimal of systemic exposure. This 
technique was further refined with the introduction drug 
eluting beads (DEB) loaded with irinotecan (DEBIRI), 
and the first exploratory trial on DEBIRI‑TACE for mCRC 
was published by Aliberti in 2006 (7). Today, the use of 
DEBIRI-TACE for mCRC is supported by several obser-
vational studies and two published randomized trials (8,9), 
yet several unclarified issues regarding the optimal patient 
selection and technique still renders an unsettled place 
for DEBIRI-TACE in the overall treatment landscape for 
mCRC (10).
Cell-free DNA (cfDNA) constitutes all circulating DNA 
fragments, both mutant and non-mutant alleles, and can be 
detected and quantified in both healthy individuals, patients 
with various medical disorders and the highest values are seen 
in cancer patients (11). Since the first report of circulating 
nuclear acids in the blood stream in 1948 (12), emphasis on 
cancer patients was enhanced by Leon in 1977 (13). During the 
past decades, there has been a growing interest in the utility 
of cfDNA in various aspects of CRC management, both for 
early stage CRC (14) and a recent meta-analysis of 10 trials has 
shown a pronounced prognostic value of cfDNA for patients 
receiving systemic palliative chemotherapy (15).
In this study, we first report the results from a single center 
phase II study of DEBIRI‑TACE plus intensified chemotherapy 
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as first‑line treatment for patients with liver limited mCRC. 
Second, we describe results of total cfDNA measured in 
plasma samples.
Materials and methods
Study design and ethics. This was an open-label phase II 
trial conducted at Aarhus University Hospital in co-operation 
between the Departments of Oncology, Radiology and Surgical 
Gastroenterology (Aarhus, Denmark). The aim was to inves-
tigate the feasibility, toxicity and efficacy of DEBIRI‑TACE 
treatment with concomitant mFOLFOX6 as a first‑line treat-
ment for patients with liver limited mCRC. Patients were 
recruited from December 2012 to February 2014. The study 
planned to include 50 patients, but was stopped prematurely 
following the inclusion of 15 patients, by the decision of the 
study board and sponsor.
All patients included received a thorough verbal and 
written information and a signed consent was received prior 
to any protocol treatment. The protocol was approved by the 
National Board of Health (EudraCT no. 2012-000987-11), 
the Data Monitor Committee (J.nr. 2012-41-0370) and the 
Regional Ethics Committee (no. 1-10-72-306-12).
Patients and eligibility. Patients eligible for this study were 
newly diagnosed patients with liver limited mCRC not being 
candidates for any standard local treatment e.g., liver resection, 
RFA or SBRT. All potential candidates were systematically 
reviewed at a multidisciplinary hepato-pancreatic tumor board 
with experienced experts in radiology (including invasive radi-
ology), oncology and liver surgery. Patients judged potentially 
eligible for local treatment in case of tumor shrinkage were 
allowed inclusion.
Key inclusion criteria were: Age >18 years, WHO 
Performance Status (PS) of 0‑1, verified metastatic colorectal 
adenocarcinoma with no extra hepatic disease, less than 50% 
of the liver parenchyma involved and satisfactory organ func-
tion. Key exclusion criteria were: Presence of other malignant 
disease, prior chemotherapy within 6 months, trombo-embolic 
disease and factors not allowing for femoral artery access.
Treatments and procedures. The treatment scheme consisted 
of initially up to 4 DEBIRI-TACE treatments concomitant with 
systemic chemotherapy of mFOLFOX6 (5-Fluororacil, leucov-
erin, Oxaliplatin) + bevacizumab 24 h after embolization. Each 
lobe was treated twice with a 4 weeks interval, so patients with 
bi-lobar involvement received biweekly treatment alternating 
the lobes, allowing for up to 4 embolizations. Subsequent to the 
4 DEBIRI-TACE treatments patients continued with systemic 
chemotherapy consisting of FLIRI (5‑fluorouracil, leocoverin, 
Irinotecan) + bevacizumab for up to a total of 6 months treat-
ment, which was the current standard of care.
Patients were systematically evaluated by CT scan of chest 
and abdomen at baseline and at weeks 8, 16 and 24 (end of 
treatment). All imaging was reviewed at the multidisciplinary 
tumor board and patients were considered for resection, RFA 
or SBRT if eligible. After completion of treatment a follow-up 
schedule of CT scan, clinical exam and CEA measurements 
were done every three months. At time of progression, patients 
were considered for all available standard treatment options.
All chemo-embolizations were done by experienced inva-
sive radiologist using a femoral approach catheterization of the 
hepatic artery in local anesthesia. The vascular anatomy was 
identified by angiogram prior to the delivery of the irinotecan 
loaded beads of 70-150 µm in diameter. A microcatheter was 
placed in the tumor feeding artery if possible. Otherwise in 
the left or right hepatic artery, peripherally to extrahepatic 
branches. The embolic procedure was given with a solution of 
5 mg of irinotecan pr ml in repeated doses until a maximum of 
40 ml were administered or until a decreased flow was recog-
nized. Injection of solution was monitored under fluoroscopy 
to ensure forward flow. Occlusion of tumor feeding artery was 
avoided.
Patients were hospitalized during the DEBIRI-TACE 
procedure, while standard systemic chemotherapy was 
given in out-patient clinic. According to protocol, a regimen 
of supportive care was applied consisting of anti-emetics 
(Ondanstron 8 mg, emperal 20 mg, methylprednisolone 
80 mg), antibiotics (piperacillin/tazobactam 4/0.5 g 1 h prior 
to embolization), analgesics (morphine 10 mg) and sedative 
(diazepam 10 mg). Patients received hydration with saline and 
were monitored with electrocardiogram, pulsoximetri and 
blood pressure measurements.
Outcome. The primary endpoint of this study was response 
rate, and secondary endpoints were survival, toxicity and 
translational research. Response evaluation was done 
using the Response Evaluation Criteria in Solid Tumors 
(RESCIST 1.1) (16) classifying patients as either a complete 
response (CR), partial response (PR), stable disease (SD) or 
progressive disease (PD). The best obtained response allowed 
for calculation of the response rate. Patients were classified as 
No Evidence of Disease (NED) if no visible residual disease 
was detected on a CT scan.
Toxicity and adverse events (AE) were registered prospec-
tively during the trial and recorded using the Common 
Terminology Criteria for Adverse Events (CTC) v3.0. (17). 
Pain was further quantified by the visual analogue score 
(VAS) (18) ranging from 0-10.
Biomarkers. Blood samples for translational use were drawn at 
baseline, prior to each DEBIRI-TACE, 24 h post-embolization 
(concurrent with mFOLFOX6) and prior to each subsequent 
cycle of protocol treatment.
Analysis of cfDNA was done using a f luorescent 
assay for cfDNA quatificantion as originally described by 
Goldshtein et al (19) and modified by our group (20). In brief, 
40 µl plasma we used, adding SYBR® Gold Nucleic Acid 
Gel Stain (1:8,000). The quantification of fluorescence was 
performed with a 96‑well fluorometer (Infinite F200 PRO; 
Tecan Group, Ltd., Mannedorf, Switzerland) at an emission 
wavelength of 535 nm and an excitation wavelength of 485 nm 
in a black 96-well plate (Bio-Plex Pro Flat Bottom Plates; 
Bio-Rad Laboratories, Inc., Hercules, CA, USA).
DNA standards were prepared from Human Control 
Genomic DNA (Thermo Fisher Scientific, Inc., Waltham, 
MA, USA) diluted with a 10% bovine serum albumin (BSA; 
Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) solution. 
The concentrations of the samples were calculated from a 
standard curve.
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For determining the definitive concentration of cfDNA in 
each sample, we calculated the median value of four measure-
ments, removing outliers according to Dixons q-test if the 
standard deviation exceeded 10%.
Statistics. Descriptive statistics were applied reporting cate-
gorical variables as counts and percentages and continuous 
variables by median values and 95% confidence interval 
(95% CI).
For analysis of survival we used the Kaplan-Meier method 
and due to the small sample size (n=14) we used descriptive 
statistics. Survival was calculated from the date of inclusion 
until death or censoring at end of follow-up (September 2017). 
Progression free survival (PFS) was defined as time until 
death, progression or censoring. For analysis of the prognostic 
value of the baseline cfDNA we stratified patients by the 
75th quartile. For analysis of the cfDNA change during the 
4 DEBIRI-TACE procedures we only included those patients 
who completed all 4 scheduled treatments (n=11).
For analysis of contingency tables, we applied Fischer's exact 
test due to the small sample size. Comparison of continuous 
variables was done by linear regression analysis. P<0.05 was 
considered to indicate a statistically significant difference.
All calculations and data management were performed 
using STATA version 14.1 (StataCorp LP, College Station, TX, 
USA).
Results
Patients and treatment. Fifteen patients were included, 
following the exclusion of one patients due to a protocol viola-
tion (9 days after inclusion), 14 patients underwent treatment 
and a median follow-up of 1.7 years (95% CI: 0.5-2.9 years). 
The study population consisted of 8 males and the median 
age was 66 (range 43-74 years). Nine patients had a colonic 
primary cancer and the median number of liver metastases 
at baseline was 10 (range 1-60) with a median size of 55 cm 
(95% CI: 39-92 cm). Details on baseline characteristics are 
displayed in Table I. A total of 49 chemoembolization proce-
dures were performed with a mean of 3.5 treatments pr patient. 
The median total dose of irinotecan embolized pr patient was 
345 mg (95% CI: 243-395 mg). Eleven patients received the 
scheduled 4 DEBIRI/FOLFOX treatments while 7 patients 
completed the post-DEBIRI/FOLFOX planned systemic 
chemotherapy with FLIRI + bevacizumab.
Outcome. Among the 14 patients in this cohort the best 
obtained response during treatment was PR (n=7), and SD 
(n=4), while the remaining patients (n=3) were not assessable 
for response evaluation due to failure to complete the sched-
uled CT scans (withdrawal of consent n=2, dead n=1). The 
corresponding response rate according to RECIST 1.1 was 
50%. Despite early response to treatment 2 patients developed 
radiological PD during the treatment course. Six patients were 
converted to eligibility for liver resection and/or RFA and 
2 patients achieved status of NED (Table II).
The median progression free survival (PFS) and overall 
survival (OS) of all patients (n=14) were 240 days (95% CI: 
161-357) and 522 days (95% CI: 174-1054) respectively, and the 
Kaplan-Meier curves are displayed for OS in Fig. 1 and PFS in 
Fig. 2. By the end of follow-up (September 1, 2017) 13 patients 
had died and the patient remaining alive was censored.
Toxicity. A total of 187 AE (all grades) were documented 
and 25 AE of grade 3 or higher (Table III). Twelve patients 
(86%) experienced a minimum of grade 3 toxicity. The most 
common grade 3 or higher toxicities were nausea/vomiting, 
fatigue, diarrhea and pain. Three patients experienced severe 
organ specific complications (pancreatitis n=1, bowel perfora-
tion n=1 and kidney failure n=1). One treatment related death 
was recorded (kidney failure).
The median VAS score for patients was 7.5 (95% CI: 
3.7-9.0). The median dose of supplemented extra orally 
administered morphine was 45 mg (95% CI: 20-180 mg) for 
all completed DEBIRI TACE treatments with a wide range of 
0 to 450 mg.
Biomarkers. The baseline values of CEA, LDH and cfDNA 
were 228 µg/l (95% CI: 54-1,131 µg/l), 296 U/l (95% CI: 
189-454 U/l) and 1.10 ng/µl (95% CI: 0.77-1.16 ng/µl), with 
one missing value for the latter. A regression analysis between 
cfDNA and CEA respectively LDH demonstrate a trend for 
correlation in linear regression analysis for LDH (P=0.06) and 
CEA (P=0.17) with one outlier removed from the dataset.
Separating patients by the 75th quartile of the baseline 
cfDNA showed a median OS of 512 days (95% CI: 172-870) 
(n=11) for patients with a baseline below the 75th quartile, and 
274 days (95% CI: 274-NA) (n=2) for patients above the 75th 
quartile.
Examining the change in cfDNA during the 8 weeks of 
DEBIRI-TACE, 6 patients with a decline in cfDNA above the 
median value had an OS of 870 (95% CI: 172-NA) days, while 
those with a cfDNA decline below the median (n=5) has an OS 
of 362 days (95% CI: 201-NA).
Handling the response rate as a categorical variable as 
PR/CR vs. not PR/CR in a 2x2 table with the median cfDNA 
at baseline did not show significance between response and 
baseline cfDNA (P=0.9).
Changes in the concentration of cfDNA during the treat-
ment course were seen for all patients. All, except one, had 
a change in cfDNA level in the blood sample 24 h after the 
first chemo‑embolization. Across all patients, the dynamic of 
cfDNA was more pronounced following the first chemo‑embo-
lization than the second. Later in the treatment course, the 
data are limited by missing blood samples post-DEBIRI and 
post-progression. Only six patients had blood samples avail-
able beyond four months of treatment, where one patient had 
an increase in cfDNA preceding the radiologic evidence of PD 
(patient no. 1, Fig. 3). For the remaining five patients we report 
a very heterogeneous pattern, although a tendency for a drop in 
cfDNA for patients with SD/PR. This is illustrated (Fig. 4) by 
the disease course for patient no. 8 where a decline in cfDNA 
preceded the status of NED.
Discussion
In this study we report the feasibility, efficacy and toxicity 
of DEBIRI‑TACE/mFOLFOX6 bevacizumab as a first‑line 
treatment for newly diagnosed mCRC. In brief, we found a 
response rate of 50%, a median PFS of 240 days (8 months) 
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and a median OS of 522 days (17 months), which are outcome 
measures comparable to other studies of DEBIRI-TACE in 
the first line setting (7,8,21,22). Six patients were converted 
to eligibility for liver resection and/or RFA and 2 patients 
achieved status of NED, but relapsed post-study. Among them, 
the only patient who was still alive at end of follow-up.
In this study, the interpretation of both the clinical outcome 
and the corresponding translational research with cfDNA 
measurements are limited by the small sample size due to the 
early closure after inclusion only 15 of the planned 50 patients. 
During the trial, we saw an unexpected high level of toxicity, 
complications and failure to complete the scheduled treatment 
Table I. Patient characteristics.
  cfDNA ng/µl (95% CI)
Characteristics Number (%), n=14 baseline, median
Sex
  Male 8 (57) 1.15 (1.04-1.37)
  Female 6 (43) 0.78 (0.64-1.11)
Age (years)
  Median 66 
  Range 43-74 
T stage
  T1 0 (0)
  T2 0 (0)
  T3 4 (29) 1.15 (1.13-1.16)
  T4 8 (57) 0.99 (0.65-1.30)
  TX 2 (14) 0.97 (0.8-1.13)
N stage
  N0 1 (7) 1.01 (1.01-1.01)
  N1 3 (21) 1.13 (0.75-1.43)
  N2 4 (29) 1.06 (0.64-1.24)
  NX 6 (43) 1.11 (0.65-1.15)
Site of primary
  Colon 9 (64) 1.10 (0.75-1.23)
  Rectal 5 (36) 1.07 (0.65-1.16)
Number of livermets (baseline)
  Median 10
  Range 1-60
Size of largest livermet (baseline, cm)
  Median (95% CI) 55 (39-92)
  Range (cm) 2.5-18
RAS/BRAF mutation
  Mutation 4 0.88 (0.64-1.15)
  Wild-type 9 1.13 (0.86-1.30)
  Unknown 1 0.8
Dose irinotecan (mg)
  Median (95% CI) 345 (243-395)
Debut of metastases
  Synchronous   3 (21) 1.16 (1.01-1.43)
  Metachronous 11 (79) 1.03 (0.68-1.14)
Number of embolization
  Median 4
  Range 1-4
T, T‑stage of primary; N, N‑stage of primary; CI, confidence interval; cfDNA, cell free DNA; RAS/BRAF, RAS/BRAF oncogene status in 
archival tissue.
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course of 6 months. These difficulties are not reported to the 
same degree in the aforementioned studies (7,8,21,22) where 
DEBIRI-TACE is reported as a safe and well tolerated treatment.
It is a hypothesis, that the challenges encountered in our study 
is due to the intense treatment of combining DEBIRI-TACE with 
systemic combinations chemotherapy of mFOLFOX6 + beva-
cizumab, which in itself can be a toxic treatment. This 
combination was also examined by Martin et al (9) who random-
ized 60 patients between DEBIRI-FOLFOX-bevacizumab 
vs. DEBIRI alone, and found an increased response rate 
and PFS in the first group. Furthermore, they found toxicity 
Table II. Response obtained at the CT scan at 8 weeks 
(post-DEBIRI-TACE) and the best obtain response during the 
6 months of scheduled treatment with CT scans at week 8, 16 
and 24.
 CT at week 8 Best obtained






Conversion to eligibility 0 6
for RFA/resection
Obtained status of NED  0 2
PD, progressive disease; SD, stable disease; PR, partial regression; CR, 
complete regression; NA, not assessable; NED, No evidence of disease; 
RFA, radio frequency ablation; CT, computed tomography.
Figure 1. Kaplan-Meier curve showing the overall survival of all patients 
(n=14) from time of inclusion.
Figure 2. Kaplan-Meier curve showing the progression free survival of all 
patients (n=14) from time of inclusion. 
Table III. Toxicity of grade 3 or higher.
 Number of patients developing 






Bowel perforation 1 (7)
Kidney failure 1 (7)
Infection (non neutropenic) 1 (7) 
Figure 4. Treatment course for patient #8 and corresponding level of cell-free 
DNA (cfDNA). A peak of cfDNA was noted following the first 2 emboliza-
tions. Subsequently a rapid decline in cfDNA prior to status of No Evidence 
of Disease (NED) was indicated.
Figure 3. Treatment course for patient #1 showing the dynamics of cell-free 
DNA (cfDNA) and corresponding response on imaging (CT scan). This 
patient had a sharp increase in cfDNA prior to the radiological diagnosis of 
progressive disease (PD).
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of grade 3 or higher for 80% of the patients in the combina-
tion arm and for 60% in the DEBIRI only-arm. It should be 
noted, that the treatment scheme in this study was different 
with one week of separation between DEBIRI and FOLFOX, 
hence FOLFOX on days 0 and 14, and DEBIRI-TACE on 
days 7 and 21. The intensity of DEBIRI-TACE and adjacent 
FOLFOX 24 h after have not been reported previously. The 
most frequent grade 3/4 toxicities encounter in our study were 
nausea, vomiting and diarrhea, which could be attributed to the 
systemic exposure.
A growing body of evidence support an intense first‑line 
treatment for mCRC, inspired by the promising results of the 
Tribe study (23) using a purely systemic triplet combination of 
5‑fluorouracil, oxaliplatin, irinotecan (FOLFOXIRI) + beva-
cizumab yielding an OS of 31 months in the experimental arm. 
Comparison of survival between studies should be done with 
caution, although it is notable, with the short median survival 
of 17 months in this study, with the exposure to the same 
cytotoxic agents as in the Tribe study. In contrast to Tribe, the 
patients in our study all had liver limited disease, yet with a 
high burden of disease by number and size of metastases and 
baseline CEA.
Using purely descriptive statistics, we report a tendency for 
a shorter OS for patients with a baseline level of cfDNA above 
the 75th quartile. With the small sample size, we are not able 
to show any statistical significance, but the observed tendency 
is in concordance with what has previously been shown for 
cfDNA and survival for patients with mCRC (15). We saw a 
similar survival tendency for patients with a large decline in 
cfDNA level during the 4 DEBIRI-TACE treatments, having 
a numerical longer survival than patients with only a minor 
change in cfDNA.
We have analyzed the concentration of the total level of 
circulating DNA fragments, thereby not limiting our analysis 
to patients with detectable mutations in the blood (e.g., K 
or N-RAS). The advantage of total cfDNA quantification 
is a more feasible laboratory investigation in contrast to the 
traditional quantitative polymerase chain reaction (qPCR) 
techniques also requiring DNA purification. By this newly 
developed direct fluorescent assay, a quantitative measure-
ment for all patients can be obtained, including for patients 
where the circulating DNA do not habour specific mutations. 
The limitations of this approach is a potential lack further 
molecular detail, e.g., emerging of a new RAS mutated clone 
would not be recognized by this methodology.
By plotting the changes in cfDNA concentration on a time 
series with the corresponding response evaluation by a CT 
scan, it is evident that the dynamics of cfNDA warrants further 
investigations. Interestingly, all patients, but one, had a detect-
able change in cfDNA level 24 h after the first DEBIRI‑TACE. 
Due to our limited sample size and missing values, we are 
unable to demonstrate any statistical correlation between an 
early peak of cfDNA and the clinical outcome. However, illus-
trating the cfDNA course introduces the concept of molecular 
lead time, with a rising cfDNA preceding the radiologic diag-
nosis of PD (Fig. 3; patient no. 1) and a decrease in cfDNA 
prior to achieving status of NED on imaging (Fig. 4; patient 
no. 8). Early changes in circulating DNA has been describe 
by Tie et al (24) who examined 53 patients receiving first‑line 
chemotherapy and found the early changes in the tumor 
specific cfDNA could predict later response on imaging. A 
potential utility of cfDNA, either as tumor specific or as a 
total quantity, could be the introduction of molecular lead time 
in diagnosis of response or progression, as also suggested by 
Reinert et al (25) using a more detailed molecular analysis of 
tumor specific DNA.
Modern treatment of mCRC is based on a multidisci-
plinary approach including with improvements in the systemic 
therapy integrating antiangiogenic treatment, classical chemo-
therapeutic agents and anti-EGFR antibodies into a combined 
modality with radiotherapy, surgery and invasive loco-regional 
therapies. DEBIR-TACE, with or without concurrent chemo-
therapy, constitutes a part of the loco-regional toolbox, 
endorsed by the ESMO guidelines (10). We propose at 
potential role of DEBIR-TACE as a therapy option for highly 
selected patients within the framework of a clinical trial, but 
the intense combination of DEBIRI-TACE with FOLFOX 24 h 
after embolization does not seem as a feasible design for future 
studies.
In conclusion, we report the clinical outcomes using 
DEBIRI-TACE + mFOLFOX6 bevacizumab as a first-line 
treatment for liver limited mCRC with a response rate of 50% 
and a median OS of 522 days (17 months). The study was 
impaired by an unexpected high profile of toxicity and early 
closure. cfDNA analysis should be explored as biomarker in 
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